Featured Research

from universities, journals, and other organizations

Darapladib falls short in chronic coronary heart disease

Date:
March 31, 2014
Source:
American College of Cardiology
Summary:
The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to new research.

The novel inflammation inhibitor darapladib showed no primary-endpoint advantage over placebo in patients with chronic coronary heart disease treated with a high level of background care, although it did suggest possible benefits for more specific coronary artery-related endpoints, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session. STABILITY is the first study to test this inflammation-prevention mechanism for reducing the likelihood that plaque will become an artery-blocking clot.

Darapladib strongly inhibits Lp-PLA2, a biomarker of inflammation in blood vessels. In the bloodstream, Lp-PLA2 is generally found on LDL cholesterol. High Lp-PLA2 levels are a risk factor for coronary heart disease and, in animal models, are linked with vulnerable plaque, an unstable waxy buildup in arterial walls that is associated with heart attacks and strokes.

In this international, phase III double-blind trial, 15,828 patients with chronic coronary heart disease (median age 65 years) were randomly assigned to receive a 160-mg darapladib tablet or placebo once daily. No major safety concerns arose; median follow-up was 3.7 years. The primary endpoint of time to first heart attack, stroke and death from cardiovascular causes was not met. Darapladib showed no significant benefit, with 769 events (9.7 percent) compared with 819 events (10.4 percent) for placebo. However, a secondary endpoint looking at a reduction in major coronary events related to the arteries (heart attack, urgent need for angioplasty or bypass surgery, or death) was nominally significant. The darapladib group had a 10 percent relative risk reduction, with 737 events (9.3 percent) in major coronary events compared with 814 events (10.3 percent) in the placebo group.

"These events are clinically important, with substantial consequences for patients," said Harvey D. White, M.D., director of Coronary Care Unit, Green Lane Cardiovascular Unit, Auckland City Hospital, New Zealand, and a co-chair of the study. "The effects on these endpoints could support the hypothesis that inhibition of Lp-PLA2 with darapladib may alter the composition of atherosclerotic plaques to a less vulnerable state and reduce ischemic events related to coronary artery plaque progression and rupture."

Researchers were surprised to see the high rate of background care in this patient population. At baseline, 93 percent of patients were taking aspirin, 97 percent statins, 79 percent beta-blockers and 77 percent ACE inhibitors or angiotensin receptor blockers, compared with similar rates at the end of the study. "We set out to test the incremental effect of darapladib on top of optimal treatment," White said.

One intriguing finding emerged from subgroup analyses: smokers had a greater decrease in major adverse cardiovascular events than non-smokers.

"Previous studies showed that smokers have higher Lp-PLA2 levels, and it's plausible that smokers may be more responsive to Lp-PLA2 inhibition, but this finding may have occurred by chance and should be considered hypothesis generating," White said.

Ongoing analysis of biomarkers, including Lp-PLA2 levels, and genetic sub-studies of STABILITY may help provide insight about darapladib's potential effects on the prevention of coronary events in patients with stable coronary heart disease. "As with statins, it may take some time for the anti-inflammatory effect of darapladib to alter the composition of coronary artery plaque, resulting in less vulnerability and fewer coronary events," White said. The modest effect of darapladib on coronary artery-related events seen in this study may heighten interest in SOLID-TIMI 52, a phase III study of darapladib in patients with recent experience of acute coronary disease.


Story Source:

The above story is based on materials provided by American College of Cardiology. Note: Materials may be edited for content and length.


Cite This Page:

American College of Cardiology. "Darapladib falls short in chronic coronary heart disease." ScienceDaily. ScienceDaily, 31 March 2014. <www.sciencedaily.com/releases/2014/03/140331100336.htm>.
American College of Cardiology. (2014, March 31). Darapladib falls short in chronic coronary heart disease. ScienceDaily. Retrieved October 23, 2014 from www.sciencedaily.com/releases/2014/03/140331100336.htm
American College of Cardiology. "Darapladib falls short in chronic coronary heart disease." ScienceDaily. www.sciencedaily.com/releases/2014/03/140331100336.htm (accessed October 23, 2014).

Share This



More Health & Medicine News

Thursday, October 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Fears Keep Guinea Hospitals Empty

Ebola Fears Keep Guinea Hospitals Empty

AP (Oct. 23, 2014) Fears of Ebola are keeping doctors and patients alike away from hospitals in the West African nation of Guinea. (Oct. 23) Video provided by AP
Powered by NewsLook.com
Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
More People Diagnosed With TB In 2013, But There's Good News

More People Diagnosed With TB In 2013, But There's Good News

Newsy (Oct. 22, 2014) The World Health Organizations says TB numbers rose in 2013, but it's partly due to better detection and more survivors. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins